02:03 PM EDT, 09/16/2024 (MT Newswires) -- NuCana ( NCNA ) shares soared 164% amid heavy trading after the company said Saturday that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.

More than 50.1 million shares traded intraday compared with a daily average of about 138,000.

Nuvalent ( NUVL ) said Saturday that data from the ongoing parallel phase 1/2 trials of zidesamtinib and NVL-655 to treat non-small cell lung cancer showed "favorable tolerability."

Shares climbed 23%, with intraday trading volume at over 1.9 million compared with a daily average of about 344,000.

Zentalis Pharmaceuticals ( ZNTL ) said the US Food and Drug Administration lifted a partial clinical hold on studies of azenosertib, the company's novel and orally bioavailable inhibitor for advanced solid tumors.

Shares advanced 20% as intraday trading volume rose to 41.4 million versus the stock's daily average of about 1.49 million.

Price: 6.71, Change: +4.17, Percent Change: +164.09